NEW

Pryme Push-to-Talk Button Assists Surgical Teams

In the United States, there are a variety of anesthesia delivery service models in healthcare. The anesthesia care team (ACT) approach pairs physician anesthesiologists (MD) with certified anesthesiologist assistants (CAA) and/or certified registered nurse...

ECRI Names Cybersecurity Attacks the Top Health Technology Hazard for 2022

This year’s Top 10 report cautions healthcare leaders about safety concerns with IT-related security challenges, COVID-19 supply chain shortages, telehealth, medication safety, and other device risks.

Healthmark Industries Offers New Brush Rack

Healthmark Industries has introduced the Brush Rack to its ProSys Instrument Care product line, manufactured from stainless steel, the 16W x 35L inch Brush Rack is designed with 12 threaded angled pegs to hang a facilities brushes out to dry, while allowing, after...

Lazurite Submits FDA 510(k) for ArthroFree Wireless Camera System

Medical device and technology company Lazurite Holdings LLC has submitted a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for its ArthroFree wireless camera system for minimally invasive surgery, and that the submission has been accepted...

USMI Developing the First Surgical Robot for Cancer Surgery

USMI Canady Surgical System

US Medical Innovations LLC (USMI) announced that it is developing the first robotic delivery system used for cancer surgery.

The new Canady Surgical System (CSS) is a space-efficient, cost-effective, stand-alone solution for robotic assisted surgery during open, laparoscopic/mini-invasive, endoscopic, thoracoscopic and trans-oral surgical procedures.

Features of the new Canady Surgical System include Voice Command technology which frees up the surgeon and assistant to focus on the surgical procedure and perform other tasks. The system includes both Canady Hybrid Plasma (CHP) and Canady Helios Cold Atmospheric Plasma (CHCAP) as well as a flexible disposable scope and camera system.

Preloaded in the CSS are treatment-dosage protocols for over 30 different cancer types and a robotic assisted image-guided navigational mapping system that delivers personalized and targeted CHCAP cancer treatments directly to the surgical site and ablating any remaining cancer cells after the tumor is removed with the CHP.

According to Jerome Canady, MD, and CEO of USMI, “Our CHCAP technology actually ablates cancer cells without damaging surrounding healthy tissue. We recently completed a Phase 1 FDA Clinical Trail using Canady Helios™ Cold Atmospheric Plasma (CHCAP) for the treatment of recurrent and stage 4 solid tumors. We see this novel technology, delivered with the precision of robotic assisted technology, as the most exciting new form of personalized and targeted medicine being explored today.”

CHCAP has many advantages. It is performed during the surgical procedure. It is highly selective because it only targets cancer cells. And thirdly, the CHCAP treatment is personalized for specific cancer types (i.e., breast, ovarian, sarcoma, lung, colon, cervical, pancreas and other solid cancerous tumors).

The organization expects to have the new Canady Surgical System in clinical trials later this year. Protocols and site locations are being explored at this time.

For more information, visit www.usmedinnovations.com.

Previous

Next

Submit a Comment

Your email address will not be published. Required fields are marked *

X